Oral Testosterone Tridecanoate Therapy
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 15/828,320, filed Nov 30, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,881,670 | Oral Testosterone Tridecanoate Therapy In force (reinstated) · High confidence | Lipocine Inc. | In force (reinstated) | High confidence | ||
| US 11,992,496 | Oral Testosterone Therapy In force · High confidence | Lipocine, Inc. | In force | High confidence | ||
| US 12,161,651 | Oral Testosterone Therapy In force · Low confidence | Lipocine Inc. | In force | Low confidence | ||
| US 12,303,517 | Oral Testosterone Therapy In force · Low confidence | Lipocine, Inc. | In force | Low confidence | ||
| US 11,672,807 | Oral Testosterone Non-Undecanoate Therapy In force · High confidence | Lipocine Inc. | In force | High confidence | ||
| Application 15/828,320 | Oral Testosterone Tridecanoate Therapy Abandoned Abandoned Jan 2, 2020 | Lipocine Inc. | Abandoned | Abandoned Jan 2, 2020 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Lipocine Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.